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Abstract
Background: RNA interference (RNAi) is a powerful approach to study a gene function. Transgenic RNAi is an
adaptation of this approach where suppression of a specific gene is achieved by expression of an RNA hairpin
from a transgene. In somatic cells, where a long double-stranded RNA (dsRNA) longer than 30 base-pairs can
induce a sequence-independent interferon response, short hairpin RNA (shRNA) expression is used to induce RNAi.
In contrast, transgenic RNAi in the oocyte routinely employs a long RNA hairpin. Transgenic RNAi based on long
hairpin RNA, although robust and successful, is restricted to a few cell types, where long double-stranded RNA
does not induce sequence-independent responses. Transgenic RNAi in mouse oocytes based on a shRNA offers
several potential advantages, including simple cloning of the transgenic vector and an ability to use the same
targeting construct in any cell type.
Results: Here we report our experience with shRNA-based transgenic RNAi in mouse oocytes. Despite optimal
starting conditions for this experiment, we experienced several setbacks, which outweigh potential benefits of the
shRNA system. First, obtaining an efficient shRNA is potentially a time-consuming and expensive task. Second, we
observed that our transgene, which was based on a common commercial vector, was readily silenced in
transgenic animals.
Conclusions: We conclude that, the long RNA hairpin-based RNAi is more reliable and cost-effective and we
recommend it as a method-of-choice when a gene is studied selectively in the oocyte.
Background
RNA interference (RNAi) is a sequence-specific mRNA
degradation induced by double stranded RNA (dsRNA).
Briefly, long dsRNA is processed in the cytoplasm by
RNase III Dicer into 20 - 22 bp long short interfering
RNAs (siRNAs), which are loaded on the effector RNA-
induced silencing complex (RISC). siRNAs serve as
guides for cleavage of complementary RNAs, which are
cleaved in the middle of the duplex formed between a
siRNA and its cognate RNA (reviewed in detail in [1]).
RNAi is a widely used approach for inhibiting gene
function in many eukaryotic model systems. Compared
to other strategies for blocking gene functions, RNAi
provides several advantages. It can be used to silence
any gene, it is fast, relatively simple to use, and its cost
is reasonably low. RNAi is usually induced either by
delivering siRNAs or long dsRNAs into cells or by
expressing RNA-inducing molecules from a vector. A
number of strategies was developed for tissue-specific
and inducible RNAi, thus offering an attractive alterna-
tive to traditional gene targeting by homologous
recombination.
RNAi became a favorable tool to block gene function
also in mammalian oocytes. In fact, mouse oocytes were
the first mammalian cell type where RNAi was used
[2,3]. RNAi induced by microinjection of long dsRNA or
siRNA into fully-grown germinal vesicle-intact (GV)
oocytes is an excellent tool to study the role of dormant
maternal mRNAs. These mRNAs are not translated
before resumption of meiosis, so the stability of the pro-
tein product is not a factor influencing the efficiency of
RNAi. In addition, resumption of meiosis can be delayed
by compounds preventing reduction of cAMP levels in
the GV oocyte, such as isobutylmethylxantine (IBMX)
or milrinone, hence the period of mRNA degradation in
microinjected oocytes can be prolonged for up to 48
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any medium, provided the original work is properly cited.hours [4]. The ability to target also genes translated dur-
ing oocyte growth has been greatly enhanced by devel-
opment of transgenic RNAi based on oocyte-specific
expression of long dsRNA hairpin (Figure 1A, [5]). In
comparison to the traditional conditional knock-out,
transgenic RNAi is simpler, cheaper, and can produce
phenotypes of different severity, depending on the
knockdown level [5,6]. At least ten genes were efficiently
suppressed in the mouse oocyte using a long hairpin-
expressing transgene ([7] and P.S., unpublished results).
Transgenic RNAi based on long RNA hairpin expres-
s i o n ,h o w e v e r ,h a st w ol i m i t a t i o n s .F i r s t ,c l o n i n ga n
inverted repeat needed for long RNA hairpin expression
may sometimes be a difficult task. Second, long dsRNA
efficiently induces a specific RNAi effect only in a lim-
ited number of cell types (reviewed in [7]). Endogenous
RNAi manifested by the presence of endogenous siRNAs
derived from long dsRNA, was found only in oocytes
and embryonic stem (ES) cells, an artificial cell type clo-
sely related to cells of the blastocyst stage [8-10].
Because dsRNA longer than 30 bp has been reported to
trigger the interferon response [11] and sequence-inde-
pendent effects were observed in differentiated ES cells
[12], induction of RNAi with expressed long hairpin
RNA never acquired wider attention besides mouse
oocytes.
We decided to develop and test a new transgenic
RNAi vector for oocyte-specific short hairpin RNA
(shRNA) expression, which would be compatible with
RNAi vectors used in somatic cells and would be more
versatile than the traditional transgenic RNAi design
(Figure 1). First, a simple promoter swap would allow
for using the same RNAi system for blocking genes in
cultured cells or in tissues. Second, cloning shRNA-pro-
ducing vector is easier when compared to cloning large
inverted repeats. Third, a new vector would be compati-
ble with different strategies to generate transgenic RNAi
animals.
Results
Vector design
The RNAi targeting vector, named pZMP (Figure 1C)
was based on pTMP and pLMP plasmids (Open Biosys-
tems), which were selected as suitable starting vectors
for producing a vector for transgenic RNAi in mouse
oocyte. Vectors pTMP and pLMP allow for stable inte-
gration into the genome upon viral transduction and
they carry suitable restriction sites for additional modifi-
cations. Furthermore, we needed a vector where shRNA
expression would be driven by RNA polymerase II (pol
II). The first shRNA systems were driven by pol III
(reviewed in [13]). Pol II systems appeared later [14-17]
Figure 1 Schematic representation of RNAi vectors. (A) A typical RNAi transgene expressing long dsRNA hairpin under the control of oocyte-
specific ZP3 promoter [5]. (B) A shRNA expressing cassette based on the endogenous human miR-30 precursor. (C) Highlighted features and
adaptations of the pTMP plasmid to produce the expression cassette of the pZMP plasmid for transgenic RNAi in the oocyte.
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of microRNA (miRNA) biology. miRNAs are genome-
encoded small RNAs, which are loaded on the same
effector complexes as siRNAs in mammalian cells [18].
Requirement for oocyte-specific expression dictated
using a pol II-driven shRNA mimicking endogenous
miRNA. The oocyte-specific expression of shRNA (Fig-
ure 1A) is controlled by the ZP3 promoter (hence
pZMP), which is highly active during oocyte growth
[19]. The transgenic cassette is flanked by LoxP
sequences and NotI sites allowing for Cre-mediated
insertion in the genome and simple release of the trans-
gene from the plasmid for microinjection, respectively.
Finally, the EcoRI site used for insertion of shRNA was
mutated to MunI because there is another EcoRI site
present in the ZP3 promoter. Since, MunI and EcoRI
p r o d u c ec o m p a t i b l eo v e r h a n g st h es a m eo l i g o n u c l e o -
tides can be used for inserting shRNA into pTMP,
pLMP and pZMP plasmids.
Vector cloning and testing
First, we compared pTMP and pLMP vectors with three
other shRNA vectors, to assure that both parental vectors
would offer robust silencing. pTMP and pLMP essentially
differ in the promoter controlling shRNA expression.
pLMP uses the constitutively active 5’LTR promoter,
while the pTMP vector uses a modified CMV promoter
allowing for tetracycline-inducible expression. Using a
published shRNA sequence targeting firefly luciferase
[20], we generated five different vectors targeting firefly
luciferase sequence, and compared their efficiency in
transiently transfected cell lines (Figure 2A). Our results
showed that pTMP and pLMP vectors induce RNAi effi-
ciently, when compared to other shRNA vectors.
Next, we modified pLMP and pTMP plasmids by
inserting linkers with LoxP and NotI sites, which flank
the expression cassette (Figure 1C). The functionality of
LoxP sites was tested in E. coli strain expressing Cre
recombinase (Figure 2B) and we also verified that LoxP
insertion has no effect on the efficiency of RNAi induced
by these vectors (Figure 2C). Subsequently, the ZP3 pro-
moter from the published transgenic RNAi cassette [5]
was inserted in the pLMP vector (Figure 1C) and the
NotI-flanked vector backbone was exchanged with the
pTMP because it is modified to render the retrovirus-
integrated 5’ LTR transcriptionally inactive, in order to
prevent interfering with the pol II promoter driving
shRNA expression. The vector sequence was verified by
sequencing. The functionality of PGK-driven puromycin-
IRES-EGFP reporter was tested in cell culture.
Mos shRNA selection
Mos dormant maternal mRNA was selected as the target
for the new RNAi vector. Targeting Mos gene offers
several advantages. First, Mos knock-out phenotype is
manifested as sterility or subfertility, which is caused by
parthenogenetic activation of eggs in otherwise normal
animals [21,22]. This allows for simple scoring for the
null phenotype and identification of potential non-speci-
fic effects of the PGK-driven reporter system in somatic
cells. Second, maternal Mos has been targeted by micro-
injection of long dsRNA [2,3,23], siRNA [23] and by
transgenic RNAi with long dsRNA [5,24], so there is a
considerable volume of data for evaluating pZMP vector
efficiency.
To silence Mos, we designed eight different shRNA
sequences located within the Mos coding sequence (Fig-
ure 3A). Mos-targeting siRNAs were predicted by RNAi
Codex database [25], BIOPREDsi [26], RNAxs [27] and
RNAi Oligo Retriever [28] tools. Best scored siRNAs
predicted by different algorithms were inserted in pLMP
and pTMP vectors in the form of shRNA and were sub-
sequently experimentally tested to find the most effi-
cient constructs.
A Mos fragment, carrying homologous sequences to
selected shRNAs, was inserted in the 3’UTR of Renilla
luciferase and resulting reporter was used to estimate
the inhibitory potential of individual shRNAs (Figure
3B). We also tested the strand selection of most efficient
shRNAs to verify that the desired shRNA strand is effi-
ciently loaded on the RISC. In this case, we used a
Renilla luciferase reporter with the cognate Mos target
sequence inserted in the antisense orientation. Our
results suggested that the Mos mRNA targeting siRNA
strand is specifically loaded on the RISC complex, while
the other strand (so-called “passenger strand”)h a da
negligible effect on the reporter (Figure 3C). This indi-
cated an efficient loading of the correct siRNA strand.
Based on these data, we have chosen the Mos_F shRNA
sequence for further experiments and inserted it into
the pZMP plasmid. Then, NotI-flanked transgenic cas-
sette was released and, after purification, the linearized
DNA fragment was used for transgenesis by pronuclear
microinjection into once-cell embryos.
Analysis of transgenic mice
Upon embryo transfer, 56 founder (F0)m i c ew e r eb o r n .
Six of these mice were positive for the transgene by
PCR genotyping. One of the founder animals (#840)
never transmitted the transgene into the F1 generation
and one founder male (#900) did not produce any pro-
geny. F0 mice from the remaining transgenic lines
(#819, #835, #892, and #896) were fertile and trans-
mitted the transgene. These lines were expanded and
further examined. Interesti n g l y ,w en o t i c e dt h a tt h e
transgene transmission into the male progeny was
reduced in all four lines (Table 1). Whether this unique
sex-specific effect is caused by a particular transgene
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[29,30], or is an effect of a hemizygous locus in a homo-
zygous genetic background is unknown and is currently
under investigation.
Genotyping of transgenic mice should be facilitated by
ubiquitous EGFP expression. However, none of the tails
of F0 mice exhibited EGFP expression originating from
the PGK-driven puromycin-IRES-EGFP reporter cassette
in the transgene (Figure 4A). Likewise, none of the
tested tissues in F1 mice (brain, kidney, liver, spleen, tes-
tis, and oocytes) showed EGFP expression under the
stereomicroscope (Figure 4A and 4B).
To test whether the reporter is completely silenced or
the EGFP expression is below a detection limit of our
microscope, we isolated tail fibroblasts from transgenic
mice and their wild-type siblings and tested in culture
their sensitivity to puromycin and assessed the transgene
expression by RT-PCR and EGFP fluorescence by flow
cytometry and fluorescent microscopy. Results of these
experiments confirmed that the reporter cassette in the
transgene is silenced in fibroblasts of F1 mice of all
available transgenic lines (Figure 4C). We also tried to
change the genetic background by crossing the C57Bl/6
transgenic animals with BALB-C mice but it did not
help to reactivate the silenced reporter in somatic cells
(data not shown). This effect is likely due to the epige-
netic silencing of the transgene because PCR analysis of
genomic DNA showed that the transgene is intact. In
addition, transfection of the purified transgene into 3T3
fibroblasts resulted in EGFP expression (Figure 4C) and
puromycin resistance (data not shown), further support-
ing the idea that the transgene is epigenetically silenced.
Although silencing of the reporter cassette in the
transgene was disappointing, we analyzed fertility, fre-
quency of parthenogenetic activation, and Mos mRNA
levels in four available transgenic lines because the
shRNA was driven by a different promoter than the pur-
omycin-EGFP reporter and the germline undergoes
Figure 2 Functional characterization of shRNA-expressing plasmids. (A) HeLa cells were co-transfected with 50 ng of plasmids expressing
shRNA targeting firefly luciferase, 200 ng of target pGL2 plasmid and 1 ng of phRL-SV40. Firefly luciferase (FF) activity normalized according to
non-targeted Renilla luciferase activity is shown. Firefly luciferase activity in control sample (without a shRNA-expressing plasmid) was set to 1.
Values are expressed as mean +/- SEM from samples transfected at least in triplicates. (B) pTMP and pLMP plasmids carrying loxP sites were
transformed either to regular or Cre recombinase-expressing E. coli strains. Electrophoresis of isolated plasmid DNA is shown. The recombined
plasmid after Cre-mediated recombination is marked by an arrow. (C) HeLa and HEK293 cells were co-transfected with 10-200 ng of plasmids
expressing shRNA targeting firefly luciferase, 200 ng of target pGL2 plasmid, and 1 ng of phRL-SV40. Relative firefly luciferase activity compared
to control cells is shown. Firefly luciferase activity in the control sample (omitting shRNA-expressing plasmid) was set to 1. Values are expressed
as mean +/- SEM from samples transfected at least in triplicates.
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that the transgene would be active in the oocyte. How-
ever, oocytes of transgenic animals did not exhibit
parthenogenetic activation. Single-cell quantitative real-
time PCR (qPCR) showed a possible down-regulation of
Mos mRNA (up to 2-fold) in transgenic lines #819,
#835, and #892 compared to wild-type controls (Figure
5A), but it was not statistically significant when consid-
ering the variability of mRNA level in individual oocytes.
However, it is possible that a mild down-regulation was
induced in the line #835 where we observed the lowest
Mos mRNA level and qPCR analysis suggested a low
level of shRNA expression (Figure 5B). These data indi-
cate that epigenetic silencing affects the whole trans-
gene, leading to low shRNA expression, which in turn is
unable to target Mos mRNA efficiently.
Discussion
Long hairpin RNA expression has been a preferred solu-
tion for specific gene inhibition by RNAi during oocyte
growth and oocyte-to-zygote transition. At least ten dif-
ferent genes were targeted by this approach and strong
mRNA knockdown was observed in all cases ([7] and P.
S., unpublished results). Successful knockdown in the
oocytes with transgenic short hairpin systems was
reported in the mouse using Cre-recombination-acti-
vated pol III promoter-driven shRNA [31]. A ZP3 pro-
moter-driven shRNA expression in Steppe Lemming
oocytes induced an efficient RNAi [32], suggesting that
miRNA-like shRNA biogenesis is intact in rodent
oocytes.
Here, we show that experiments with pol II-driven
miRNA-like shRNA system did not meet expectations
and raised questions whether such a system represents a
more versatile and economical alternative to the long
hairpin RNA-based approach. The expected benefit of
the shRNA system, a simple production of the targeting
vector, turned out to be correct and targeting vectors
were easily produced in a single cloning step. Easy pro-
duction of different targeting vectors facilitates testing
different siRNA sequences in transient cell culture
transfections before producing transgenic animals. This
used to be an advantage over the long hairpin RNA sys-
tem, where targeting efficiency of transgenic constructs
Figure 3 Functional characterization of Mos-targeted shRNAs.(A) A schematic position of Mos-targeting shRNAs within the Mos mRNA. The
Mos coding region is represented by an arrow. (B) HeLa cells were co-transfected with 50 ng of pLMP_LoxP plasmid expressing various Mos-
targeting shRNAs and 50 ng of target Renilla luciferase plasmid carrying a fragment of Mos gene in sense orientation in the 3’ UTR, and 50 ng of
pGL4-SV40. Relative Renilla luciferase (RL) activity normalized to co-transfected untargeted firefly luciferase is shown. RL activity in the control
sample (no shRNA-expressing plasmid) was set to 1. Values are expressed as mean +/- SEM from samples transfected at least in triplicates.
Mos_F shRNA cloned into pSUPER plasmid is shown for comparison. (C) Same experimental design as in (B) except Renilla luciferase with
antisense Mos target sequence in 3’-UTR was used as a reporter.
Table 1 Overview of F1 and F2 progeny of transgenic
founder animals
Sex Transgene Number of pups in individual lines Sum %
#819 #835 #892 #896
M + 8 5 8 13 34 33.3%
- 19 12 16 21 68 66.6%
F + 20 4 20 15 59 54.6%
- 10 6 15 18 49 45.4%
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petent oocytes. To circumvent this problem, different
strategies are available now that simplify cloning of long
inverted repeats [33] and, in our experience, the trans-
genic approach with long hairpin RNA is reliable
enough that, upon verifying the correct structure of the
transgene by sequencing, we routinely proceed directly
to production of transgenic animals.
Thus, designing and cloning functional shRNAs is not
a significant advantage over producing the traditional
long hairpin-expressing transgene. A shRNA with a
defined sequence exhibits sequence-specific off-target
effects. Thus, one needs at least two different shRNAs
and/or other means to assure that off-targeting will not
interfere with interpretation of data [34,35]. This com-
plicates the production of transgenic lines because, ide-
ally, one would need to have different transgenic lines
expressing different shRNAs targeting the same gene. In
addition, obtaining effective shRNAs may also represent
a problem. While testing eight different shRNAs
designed by the best available algorithms [25-28], we
found just two good shRNAs with ~50% knockdown
effects in a transient reporter assay. This issue will be
reduced in the future as more verified shRNA sequences
will become available. Still, obtaining verified shRNAs
against oocyte-specific genes might represent a problem.
Transgenic RNAi with shRNA is not more econom-
ical. Testing different shRNAs (eight in our case)
required custom synthesis of eight long oligonucleotides
and cloning of eight targeting vectors plus cloning one
targeted reporter vector because the targeted gene was
oocyte-specific, hence not expressed in common cell
lines. This actually made the total cost of the experi-
ment higher when compared to long hairpin transgenes.
In any case, theoretical advantages became irrelevant
during the disappointing pilot experiment, where all
transgenic lines produced by traditional pronuclear
microinjection carried completely silenced transgenes in
all tissues in the F0 generation already. In contrast, long
hairpin RNAi transgenes produced by pronuclear micro-
injection in the same transgenic facility, in the same
genetic background, and carrying the same ZP3 promo-
ter induced strong knock-down effects in oocytes (PS,
unpublished results).
Figure 4 Characterization of transgenic animals. (A) EGFP expression in brain, tail and kidney of transgenic animals. Bright-field images are
shown to illustrate organ morphology. F1 generation mice from all transgenic lines were used for the analysis. EGFP expression in transgenic
mice carrying a CMV-EGFP transgene (P.S., unpublished results) is shown for comparison. (B) EGFP expression in oocytes isolated form wild-type
and transgenic animals. Bright-field images are shown to illustrate oocyte morphology. (C) EGFP expression in primary fibroblast isolated from
wild-type and transgenic animals. NIH3T3 cells transfected with pZMP plasmid were used as positive controls.
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cing being associated with the shRNA transgene
sequence/structure. First, we have never seen such a
rapid and complete silencing of a transgene in all tissues
of F0 animals and their progeny with other transgenes.
This silencing is really striking considering the same
transgene produces puromycin resistance and EGFP
expression when transiently transfected in mouse
NIH3T3 cells (Figure 4C). We speculate that, while it is
tolerated in cells during transient transfection, the unu-
sual structure of the transgene (flanking with short
inverted repeats of LoxP sites and the absence of
introns) and expression of unspliced bicistronic reporter
mRNAs carrying a viral IRES contribute to its silencing
w h e nt h et r a n s g e n ei si n t e g r a t e di nt h eg e n o m eo fa n
animal. Thus, our data show that optimization of
shRNA-expressing transgenes design is needed and that
intron-less transgenic cassette compatible with retroviral
transgenesis might be suboptimal for transgenic RNAi
in the mouse.
Conclusions
The oocyte-specific transgenic RNAi mediated by
shRNA does not have any significant advantage in terms
of labour, price, knockdown efficiency, and specificity.
Transgenic RNAi with shRNA in the oocyte might
represent an advantage only in the case when the same
gene is being studied in the oocyte and somatic cells. In
other cases, transgenic RNAi with long hairpin RNA
appears to be a better approach. Current strategies for
cloning long inverted repeats make the production of
long hairpin-expressing transgenes feasible and cost-
effective [33,36]. To our knowledge, all transgenic RNAi
experiments with long hairpin-expressing transgenes
yielded transgenic lines with strong silencing including
phenocopying the knockout phenotypes. Moreover,
detailed analysis of non-specific effects revealed remark-
able specificity of transgenic RNAi induced by long hair-
pin RNA [24], presumably because off-target effects are
minimized by processing long dsRNA into a pool of siR-
NAs with different sequences [37].
Methods
Plasmids
Renilla-Mos reporters
Renilla-Mos reporters were generated from phRL_SV40
(Promega) by inserting a Mos fragment into the Renilla
3’-UTR. The Mos fragment was amplified by PCR from
genomic DNA using Mos_XbaI_Fwd and Mos_XbaI_Rev
primers (see additional file 1: A list of oligonucleotide
sequences used in this study). PCR product was cleaved
and inserted into the XbaI site in phRL_SV40 to pro-
duce phRL_SV40_mMos and phRL_SV40_ asMos repor-
ters where the Mos fragment was inserted in a sense
and an antisense orientation, respectively.
pLMP and pTMP shRNA plasmids
For each shRNA to be inserted into pLMP and pTMP
plasmid, one long oligonucleotide was synthesized
(Sigma-Aldrich). Each oligonucleotide was used as a
template for PCR (performed according to the manufac-
turer’s instructions) using LMP_oligo.fwd and LMP_o-
ligo.rev primers. Resulting PCR product was digested by
EcoRI and XhoI and cloned into the target plasmid
digested by XhoI and EcoRI. All plasmids were verified
by sequencing.
pZMP and pZMP-Mos_F
The pZMP vector was derived from pTMP and pLMP
plasmids as follows. 5’ and 3’ LoxP and NotI sites flank-
ing the transgenic cassette were sequentially inserted
into BglII and SalI sites, respectively, in pLMP and
pTMP in a form of in vitro synthesized annealed linkers
(5’loxP.fwd/rev and 3’loxP.fwd/rev, respectively) produ-
cing pLMP_LoxP and pTMP_LoxP. Subsequently, the
EcoRI site for shRNA cloning in the pLMP_LoxP vector
was mutagenized to the MunI site using Quick Change
Figure 5 S i n g l e - c e l lq P C Ra n a l y s i so fMos knock-down and
shRNA expression in mouse oocytes. (A) Relative Mos mRNA
expression in oocytes from transgenic animals (Mos mRNA level in
wild-type oocytes is set to 1). Rabbit b-globin mRNA, which was
added to the lysis buffer at the time of collection, was used as an
external standard for data normalization. Statistical significance of
relative expression changes of Mos mRNA levels normalized to the
b-globin was analyzed by the pair-wise fixed reallocation
randomization test using the REST 2008 software. (B) Relative Mos_F
shRNA expression in oocytes from transgenic animals. All data are
expressed as mean +/- SEM from at least five oocytes.
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to manufacturer’s instructions using LMP_MunI.fwd
and LMP_MunI.rev primers.
The ZP3 promoter was amplified from the original
transgenic RNAi vector [5] by PCR using primers
ZP3_BglII_Fwd and ZP3_BglII_Rev using a Pfu DNA
polymerase. The ZP3 promoter-carrying PCR fragment
was cleaved by BglII and inserted in the BglII site in the
pLMP_LoxP plasmid to get pLMP_LoxP_ZP3 plasmid.
The correct orientation of the ZP3 promoter and the
absence of mutations were verified by sequencing.
Finally, the NotI-flanked CMV-TRE-Puromycin-EGFP
cassette in the pTMP_LoxP plasmid was replaced by the
NotI site-flanked ZP3 cassette from pLMP_LoxP_ZP3
plasmid to produce the pZMP vector ready for shRNA
insertion. The reason for this strategy was that the
pTMP_LoxP plasmid did not contain suitable restriction
sites for direct insertion of the ZP3 promoter while the
pLMP is not a self-inactivating (SIN) retroviral vector
and strong promoter present in the 5’LTR region of
pLMP would have undesirable effects on shRNA
expression.
Finally, Mos_F shRNA was inserted in the pZMP to
produce pZMP-Mos_F plasmid. The transgenic cassette
(~ 4.5 kb) was released by NotI digest, isolated by Gel
Extraction Kit (Qiagen), and purified twice using DNA
Clean & Concentrator kit (Zymo Research). The cassette
purity and integrity was verified by agarose gel electro-
phoresis before it was submitted to the transgenic
facility.
Other plasmids
Cloning of shRNAs targeting firefly luciferase (pGL2,
Promega) into pLMP, pTMP and pTRIPZ plasmids
(Open Biosystems) was performed as described above
using FL_1 primer as a template. The insert for cloning
into pSuper vector (OligoEngine) was prepared by
annealing oligonucleotides FL_2 and FL_3 and cloning
them into BglII and HindIII sites of target vector
according to the manufacturer’si n s t r u c t i o n s .Ah a i r p i n
cloned into the UI2-GFP-SIBR vector [14] was prepared
by annealing oligonucleotides FL_4 and FL_5 (see addi-
tional file 1: A list of oligonucleotide sequences used in
this study). Annealed oligonucleotides were cloned into
BpiI-cleaved vector. All plasmids were verified by
sequencing.
Cell culture
Transformed cell lines
HeLa, HEK293, and NIH3T3 cells were cultured in Dul-
becco’s Modified Eagle medium (DMEM, Sigma) supple-
mented with 10% fetal bovine serum (FBS, Gibco),
Penicillin 100 U/ml and Streptomycin 100 μg/ml
(Gibco). For transfection, cells were seeded in 24-well
plates at the initial density 30,000 (HeLa and NIH3T3)
or 60,000 (HEK293) cells per well in 0.5 ml of culture
medium. 24 hours later, cells were transfected with 500
ng of plasmid DNA per well. TurboFect (Fermentas)
was used as the transfection reagent. pBluescript (Strata-
gene) was used to equalize the total amount of DNA per
transfection. A 1 ml aliquot of fresh culture media was
added 6 hours post-transfection. Each transfection was
performed at least in duplicates. Cells were collected 48
hours post-transfection and used for analysis.
Primary tail fibroblasts culture and puromycin selection
Primary fibroblasts were prepared from tail biopsies by
collagenase treatment as described previously [38]. Pri-
mary tail fibroblasts from transgenic and wild type mice
were cultured in DMEM supplemented with 10% FBS
and Penicillin/Streptomycin at 37°C and 5% CO2 for at
least five days. Before experiment, medium was changed
and puromycin was added to the final concentration of
2.5 μg/ml. Cell culture was continued for additional 2
days until the control cells from wild-type mice died.
Dual Luciferase assay
For luciferase assays, cells were typically transfected with
50-250 ng of a firefly luciferase coding plasmid (pGL4-
S V 4 0o rp G L 2 ) ,1n go faRenilla luciferase reporter
plasmid, 50 ng of a tested hairpin-coding vector, and
pBluescript up to the total DNA amount 500 ng per
well. In some experiments, different concentrations of a
tested plasmid (20 - 450 ng) were used. Control trans-
fection did not include the shRNA-expressing vector.
Cells were harvested 48 hours post-transfection and
lysed with 150 μl of Passive Lysis Buffer (Promega). Pro-
tein amount in lysates was quantified by Protein Assay
Dye Reagent (Bio-Rad) according to the manufacturer’s
protocol. A 10 μl aliquot of each lysate was pipetted
into a 96-well plate and luciferase activity was measured
using a Dual-Luciferase Reporter Assay System (Pro-
mega) according to the manufacturer’s instructions. The
measurement was performed on the Modulus Micro-
plate luminometer (Turner BioSystems).
Mice
Production of transgenic founders
All animal experiments were approved by the Institu-
tional Animal Use and Care Committees and were in
agreement with Czech law and NIH (National Institutes
of Health) guidelines. Transgenic mice were produced
in the Transgenic core facility of the Institute of Mole-
cular Genetics Academy of Science of the Czech Repub-
lic. Briefly, fertilized donor oocytes were obtained from
super-ovulated 3-4 weeks old C57Bl/6N females
(Charles Rivers Laboratories). Hormonal stimulation was
carried out as follows: 5U of Pregnant Mare’sS e r u m
Gonadotropine (PMSG/Folligon; Intervet) was injected
into peritoneum. Forty-five hours later, 5U of human
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peritoneum and mice were mated with C57Bl/6N males.
One day later, one-cell stage embryos were isolated
from plugged females. Pronuclear injection (PNI) of
transgene DNA into male pronucleus was performed.
Embryo transfer was performed either at one-cell stage
directly after PNI or at the two-cell stage after an over-
night culture depending on the amount of foster mice
available on a specific day. Pseudopregnant CD1 females
were used as foster mothers. Females were paired with
vasectomized CD1 males (for optimal stimulation of the
female) a night before the transfer. Embryos were trans-
ferred into the oviduct (15-25 embryos per recipient,
into one or both oviducts) under sterile conditions in
SPF (specified pathogen free) area of animal house. CD1
mice were obtained from an in-house breeding.
Genotyping
The tail biopsies were obtained from 3-4 weeks old
mice. GFP expression was analyzed by fluorescent
stereomicroscope SZX16 (Olympus). Genotyping was
performed by PCR and resulting products were analyzed
by electrophoresis on 1.5% agarose gels.
Oocyte isolation and culture
Fully-grown GV-intact oocytes were obtained from
eight-week old mice 44 hours after superovulation by
intraperitoneal injection o f0 . 1m l( 5u n i t s )o fP M S G
(Folligon; Intervet). Oocytes were collected into M2
medium supplemented with 4 μg of isobutylmethyl-
xanthine (IBMX, 200 mM) to prevent resumption of
meiosis. Cumulus cells were removed with a thin glass
capillary. Isolated oocytes were either immediately ana-
lyzed by microscopy or washed twice in PBS and lysed
for single-cell qPCR analysis. GV oocytes used for meio-
tic maturation were washed five-times in M2 medium
without IBMX and cultured overnight in CZB medium
supplemented with glutamine (5 μl of 3% glutamine per
1 ml CZB)[39].
Quantitative real-time RT-PCR (qPCR)
mRNA expression in oocytes was analyzed by single-cell
qPCR [40]. Briefly, individual oocytes were washed in
PBS and placed separately in 5 μl of water. 1 μg of stuf-
fer rRNA (16S + 23S, Roche) and 15 pg of external stan-
dard rabbit b-globin mRNA (Sigma) were added to each
sample. All samples were snap-frozen and stored at -80°
C until further processing. Before qPCR, samples were
incubated at 85°C for 5 minutes to lyse oocytes and
then were placed on ice. 1 μl of Oligo(dT) primer (50
μM) or random hexanucleotides (Fermentas) and water
up to 13 μl were added to all samples. mRNA was
reverse transcribed using RevertAid M-MuLV Reverse
transcriptase (Fermentas). Reverse transcriptase was
omitted in control (-RT) samples. Resulting cDNA was
diluted 3:2 with water and a 3 μla l i q u o tw a su s e da sa
template for qPCR. qPCR was performed on the iQ5
machine (Bio-Rad) using Maxima SYBR Green qPCR
Master Mix (Fermentas). Specific primers for mouse
Mos and rabbit b-globin mRNAs were used (see addi-
tional file 1: A list of oligonucleotide sequences used in
this study). qPCR data werea n a l y z e db yt h ei Q 5s o f t -
ware (Bio-Rad) and values of crossing points (CPs) were
evaluated for each reaction. PCR efficiency was calcu-
lated for each individual reaction using the exponential
regression model [41] and CPs values were corrected
accordingly. Statistical significance of relative expression
changes of Mos mRNA levels normalized to the external
b-globin standard was analyzed by the pair-wise fixed
reallocation randomization test using the REST 2008
software [42].
Additional material
Additional file 1: A list of oligonucleotide sequences used in this
study. A table listing sequences of all oligonucleotides used in this
study.
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